Share
News
-
25 July 2008 /Product information
EMEA recommends restricting the use of oral moxifloxacin-containing medicines
The European Medicines Agency (EMEA) has reviewed the safety of moxifloxacin-containing medicines for oral use. The EMEA has concluded that these medicines should only be prescribed for the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis and community-acquired pneumonia when other antibiotics cannot be used or have failed.
-
25 July 2008 /Product information
EMEA recommends restricted use of oral norfloxacin-containing medicines in urinary infections
The European Medicines Agency has recommended restricting the use of oral norfloxacin-containing medicines in urinary infections.
-
25 July 2008 /Product information
No increased risk of developing cancer for patients having taken Viracept® contaminated with ethyl mesilate
Following a review of a number of toxicology studies, the European Medicines Agency (EMEA) has confirmed that there is no increased risk of development of cancer for patients who have taken contaminated Viracept® (Nelfinavir).
-
15 July 2008 /Product information
Warning against the product Viamax Energizer
The Danish Medicines Agency has become aware of the product Viamax Energizer, which is sold on the internet as a product providing energy. An analysis carried out by the Swedish Medical Products Agency has shown that the product contains the active substances levodopa and theophylline, which does not appear from the packages.
-
03 July 2008 /Product information
Recall of Nobligan® oral drops in Denmark
In cooperation with the Danish Medicines Agency, Grünenthal Aps has decided to recall all packs of Nobligan® oral drops, 100mg/ml (pack sizes of 10 ml and 96 ml) in Denmark.
